SCHEMBL2910477

SCHEMBL2910477

Cc1ccc(OCc2ccccc2)cc1C(=O)NCc1ccc(C(=O)O)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.59
RECQL P46063 1/20 0.57
NR4A1 P22736 1/20 0.56
NR4A2 P43354 1/20 0.56
NR4A3 Q92570 1/20 0.56
NR1H4 Q96RI1 3/20 0.55
SMN1; SMN2 Q16637 2/20 0.55
MEN1 O00255 2/20 0.55
KMT2A Q03164 2/20 0.55
MAOB P27338 1/20 0.53
KLKB1 P03952 1/20 0.53
SRD5A2 P31213 1/20 0.52
SGMS2 Q8NHU3 1/20 0.52
TSHR P16473 1/20 0.51
SPHK2 Q9NRA0 1/20 0.51
CTDSP1 Q9GZU7 1/20 0.51
MMP13 P45452 1/20 0.50
RXRA P19793 1/20 0.50
RXRB P28702 1/20 0.50
RXRG P48443 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2905180 0.91 NR1H4 (0.56) LMNARECQLNR4A2NR1H4SMN1; SMN2
SCHEMBL2910569 0.90 RXRA (0.63) LMNARECQLNR4A2NR1H4SMN1; SMN2
SCHEMBL2910555 0.90 NR4A2 (0.63) LMNARECQLNR4A2NR1H4MAOB
SCHEMBL2902692 0.86 LMNA (0.56) LMNANR4A1NR4A2NR4A3SMN1; SMN2
SCHEMBL13844837 0.84 LMNA (0.51) LMNARECQLNR1H4SMN1; SMN2
SCHEMBL12999007 0.82 SMN1; SMN2 (0.55) LMNARECQLNR1H4SMN1; SMN2MEN1
SCHEMBL2909519 0.81 PPARG (0.56) LMNANR1H4SMN1; SMN2MEN1KMT2A
SCHEMBL2905163 0.81 RAB9A (0.62) LMNANR4A2SMN1; SMN2MAOBRXRA
SCHEMBL12998996 0.80 NPC1 (0.56) LMNARECQLSMN1; SMN2MEN1KMT2A
SCHEMBL12999006 0.80 MRGPRX4 (0.57) LMNARECQLNR4A2SMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2220029-B1 Benzamide compounds and their use as prostaglandin E4 receptor agonists GLAXO GROUP LTD (GB) 2013-11-20 EP claimed
US-8293798-B2 Compounds GLAXO GROUP LIMITED (GB) 2012-10-23 US claimed
US-20100305166-A1 NOVEL COMPOUNDS GLAXO GROUP LIMITED 2010-12-02 US claimed
EP-2220029-A1 NOVEL COMPOUNDS Glaxo Group Limited (GB) 2010-08-25 EP claimed
WO-2009056582-A1 NOVEL COMPOUNDS GLAXO GROUP LIMITED (GB) 2009-05-07 WO claimed
EP-2220029-B1 Benzamide compounds and their use as prostaglandin E4 receptor agonists GLAXO GROUP LTD (GB) 2013-11-20 EP disclosed
US-8293798-B2 Compounds GLAXO GROUP LIMITED (GB) 2012-10-23 US disclosed
US-20100305166-A1 NOVEL COMPOUNDS GLAXO GROUP LIMITED 2010-12-02 US disclosed
EP-2220029-A1 NOVEL COMPOUNDS Glaxo Group Limited (GB) 2010-08-25 EP disclosed
WO-2009056582-A1 NOVEL COMPOUNDS GLAXO GROUP LIMITED (GB) 2009-05-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305166-A1 NOVEL COMPOUNDS F12, C1R, RPS4X LMNA 1702/4885RECQL 244/4885NR4A1 145/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.